UroGen Expands Oncology Pipeline with IntraGel Collaboration, $7M Investment
Event summary
- UroGen secures research license and exclusive options to develop up to three oncology products using IntraGel’s SRGel platform.
- Exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer, following Phase 2 study completion.
- UroGen invests up to $7 million in IntraGel’s equity securities as part of the strategic agreement.
- SRGel platform is designed for biodegradable, sustained-release drug delivery, potentially applicable across multiple solid tumors.
- Early clinical data for TumoCure showed low systemic cisplatin exposure and early indications of anti-tumor activity in heavily pretreated patients.
The big picture
UroGen’s collaboration with IntraGel represents a strategic move to diversify its oncology pipeline and enhance its technological capabilities in localized drug delivery. The $7 million investment underscores UroGen’s commitment to expanding its reach beyond urothelial cancers into broader solid tumor indications. This partnership aligns with the broader industry trend of leveraging advanced drug delivery technologies to improve therapeutic outcomes and minimize systemic toxicities.
What we're watching
- Pipeline Expansion
- Whether UroGen can successfully develop and commercialize up to three additional oncology products using the SRGel platform.
- Clinical Development
- The pace at which TumoCure advances through Phase 2 clinical trials and its potential regulatory approval.
- Technological Integration
- How effectively UroGen integrates IntraGel’s SRGel technology with its existing RTGel platform to enhance localized drug delivery.
Related topics